Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Gang Wang et al.|Signal Transduction and Targeted Therapy|2025Cited by 20